GLP-1 Agonists and Heart Rate: Prevalence and Clinical Significance

GLP-1 receptor agonists have transformed care for type 2 diabetes and obesity. From improving glycemic control to aiding significant weight loss, they offer broad metabolic benefits. However, one less discussed but increasingly observed effect is their potential to raise resting heart rate.

While often dismissed as a benign side effect, this modest but measurable change in pulse may have more nuanced implications, especially in certain populations. Understanding how and why GLP-1 medications affect heart rate helps guide safer, more individualized care.

What Are GLP-1 Agonists?

Glucagon-like peptide-1 receptor agonists (GLP1-RA) mimic the body’s natural GLP-1 hormone, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety. These agents include:

• Tirzepatide (Mounjaro, Zepbound – though technically a dual GIP/GLP-1 receptor agonist)
• Semaglutide (Ozempic, Wegovy, Rybelsus)
• Liraglutide (Victoza, Saxenda)
• Dulaglutide (Trulicity)
• Exenatide (Byetta, Bydureon)

They are widely used in both endocrinology and obesity medicine for managing diabetes, weight, and cardiovascular risk.

How Common Is an Increased Heart Rate?

A modest increase in resting heart rate is a class effect across most GLP-1 agonists. On average, resting heart rate increases by 2–4 beats per minute, though individual responses vary.

Reported Prevalence:

• Liraglutide: Up to 30% of users show a measurable rise in heart rate.
• Semaglutide: Average increase of 2–3 bpm in trials, with a subset reaching 10 bpm or more.
• Dulaglutide: Consistently associated with small increases across multiple studies.
• Tirzepatide: Shows similar trends, though long-term cardiovascular outcome data are still emerging.

This phenomenon often occurs within the first few weeks of starting therapy and tends to persist with ongoing use.

Why Does It Happen?

The exact mechanism remains unclear, but several possibilities have emerged:

• Autonomic Modulation: GLP-1 agonists may reduce parasympathetic (vagal) tone or enhance sympathetic drive, leading to a faster resting heart rate.
• Central Nervous System Effects: Some GLP-1 receptors are located in the brainstem and hypothalamus, regions involved in cardiovascular control.
• Direct Cardiac Effects: GLP-1 receptors exist in the heart, potentially influencing pacemaker activity or conduction pathways.

Interestingly, this effect seems independent of weight loss, which usually lowers heart rate. In fact, the more weight a person loses, the more apparent this GLP-1–mediated heart rate increase may become.

Summary Table

Factor	Details
Average Heart Rate Increase	2–4 bpm
Timing	Within 1–4 weeks of initiation
Prevalence	Up to 30% in some trials
Persistence	Sustained during continued treatment
Clinical Significance	Varies by individual; more relevant in high-risk patients

Clinical Implications: Who Should We Monitor More Closely?

For most patients, this small increase carries little or no consequence. But for others, it may signal or contribute to deeper concerns.

Consider closer attention in:

• Patients with preexisting tachycardia or arrhythmias (e.g., atrial fibrillation, POTS)
• Heart failure patients, especially with preserved ejection fraction (HFpEF)
• Those with high resting heart rate (>85 bpm) before starting
• People on beta-blockers or other rate-controlling medications
• Athletes or very fit individuals with low resting pulse who may feel symptoms from small increases

Case Examples from Practice

A few cases from our practice in Montgomery County, Maryland, illustrate this variation:

• A 72-year-old man with mild heart failure (HFpEF) on tirzepatide experienced a resting heart rate increase from 78 to 90 bpm. His blood pressure was stable, but the decision was made to reduce the dose and continue close follow-up.
• A 54-year-old woman with type 2 diabetes and sleep apnea started semaglutide. Her resting heart rate rose from 68 to 82 bpm. She reported no symptoms, and her blood pressure remained stable. We continued therapy with closer monitoring.
• A 32-year-old athlete with insulin resistance began semaglutide for weight loss. Her pulse increased from 54 to 70 bpm. While this was within normal limits, she noted subtle changes in recovery time after workouts. We reassured her and monitored her fitness metrics over time.
• A 65-year-old patient with atrial fibrillation experienced poor rate control after adding dulaglutide. We paused therapy temporarily and collaborated with cardiology for better rhythm management.
• A 42-year-old man with obesity and borderline hypertension experienced palpitations one month into liraglutide. Resting heart rate increased from 72 to 88 bpm. After switching to a lower dose and adding magnesium taurate, his symptoms improved.

Does Increased Heart Rate Offset the Cardiovascular Benefits?

This question is key—and still evolving.

Large outcome trials like LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown clear cardiovascular benefits despite the heart rate increase. These benefits likely stem from:

• Better glycemic control
• Lowered insulin resistance
• Weight loss
• Reduced inflammation
• Improved endothelial function

So far, the net effect seems favorable. However, in patients with existing heart disease, nuanced risk-benefit decisions still matter.

Why Holistic, Individualized Care Matters

Not all patients respond the same way. A thoughtful approach that includes resting heart rate, cardiovascular history, and lifestyle can guide smarter decisions.

For example, pairing GLP-1 therapy with aerobic conditioning, magnesium support, or adjusting other medications can often rebalance the picture. As an obesity specialist and hypertension specialist, I often assess the broader context of sleep, autonomic tone, thyroid function, and electrolyte status.

Virtual care also allows us to monitor trends more consistently, making this a manageable concern with the right tools.

Summary

A modest increase in resting heart rate is a well-recognized effect of GLP-1 receptor agonists. While usually mild and clinically benign, this change deserves attention—especially in those with heart rhythm disorders or other cardiovascular risk factors.

Understanding this effect allows for better dosing, closer monitoring, and more confident use of these powerful metabolic tools. It’s another reason why GLP-1 therapy, like all endocrine care, benefits from a personalized, integrated, and common-sense approach.